The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
SWOG 1211: A randomized phase I/II study of optimal induction therapy for newly diagnosed high-risk multiple myeloma (HRMM).
Saad Zafar Usmani
Consultant or Advisory Role - Celgene; Onyx
Honoraria - Celgene; Millennium; Onyx
Research Funding - Array BioPharma; Celgene; Janssen; Onyx; Senesco Technologies
Antje Hoering
No relevant relationships to disclose
Rachel Sexton
No relevant relationships to disclose
Sikander Ailawadhi
Honoraria - Millennium
Jatin J. Shah
Honoraria - Array BioPharma; Bristol-Myers Squibb; Celgene; Millennium; Onyx
Research Funding - Array BioPharma; Bristol-Myers Squibb; Celgene; Millennium; Onyx
Sandi Fredette
No relevant relationships to disclose
Brian G. Durie
No relevant relationships to disclose
Jeffrey A. Zonder
No relevant relationships to disclose
Madhav V. Dhodapkar
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Celgene
S. Vincent Rajkumar
No relevant relationships to disclose
Anuj Kumar Mahindra
No relevant relationships to disclose
Todd M. Zimmerman
No relevant relationships to disclose
Paul G. Richardson
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Millennium
Research Funding - Bristol-Myers Squibb; Celgene; Millennium
Robert Z. Orlowski
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Millennium; Onyx
Research Funding - Bristol-Myers Squibb; Celgene; Millennium; Onyx